Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.

JCI insight - 8 Apr 2021

Shimomura Iwao, Watanabe Naoaki, Yamamoto Tomofumi, Kumazaki Minami, Tada Yuji, Tatsumi Koichiro, Ochiya Takahiro, Yamamoto Yusuke

Abstract excerpt

Lung cancer with oncogenic KRAS makes up a significant proportion of lung cancers and is accompanied by a poor prognosis. Recent advances in understanding the molecular pathogenesis of lung cancer with oncogenic KRAS have enabled the development of drugs, yet mutated KRAS remains undruggable. We performed small-molecule library screening and identified verteporfin, a yes-associated protein 1 (YAP1) inhibitor;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endoplasmic Reticulum Stress

Share to Gene Expression Regulation, Neoplastic

Share to Mice, Inbred BALB C

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Share to YAP-Signaling Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 33830081
DOI: 10.1172/jci.insight.137876
PMCID: PMC8119185

Genes

KRAS
YAP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.PMID 33830081Read ↗

Current therapy of KRAS-mutant lung cancer.Semantic proximity Read ↗

Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis.Semantic proximity Read ↗

Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.Semantic proximity Read ↗

Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer.Semantic proximity Read ↗

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancerSemantic proximity Read ↗

SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.Semantic proximity Read ↗

Oncogenic KRAS confers chemoresistance by upregulating NRF2.Semantic proximity Read ↗

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survivalSemantic proximity Read ↗

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.Semantic proximity Read ↗

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancerSemantic proximity Read ↗

Selective Targeting of Ras Mutant Cancers via a New Small MoleculeSemantic proximity Read ↗

Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.